|
KMID : 0988920160140020152
|
|
Intestinal Research
2016 Volume.14 No. 2 p.152 ~ p.163
|
|
|
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn’s disease
|
|
Kai-Chun Wu
Zhi Hua Ran
Xiang Gao
Minhu Chen
Jie Zhong
Jian-Qiu Sheng
Michael A Kamm
Simon Travis
Kori Wallace
Nael M Mostafa
Marisa Shapiro
Yao Li
Roopal B Thakkar
Anne M Robinson
|
|
|
Abstract
|
|
|
Background/Aims: This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn’s disease (CD).
Methods: Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220?450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8?26; patients received 40 mg adalimumab every other week. Serum adalimumab concentration and change from baseline in fecal calprotectin (FC) were measured during the double-blind period. Clinical remission (CDAI <150), response (decrease in CDAI ≥70 points from baseline), and change from baseline in hs-CRP were assessed through week 26. Nonresponder imputation was used for missing categorical data and last observation carried forward for missing hs-CRP/FC values. No formal hypothesis was tested. Adverse events were monitored.
Results: Mean adalimumab serum concentrations during the induction phase were 13.9?18.1 μg/mL (160/80 mg group) and 7.5?9.5 μg/mL (80/40 mg group). During the double-blind period, higher remission/response rates and greater reductions from baseline in hs-CRP and FC were observed with adalimumab 160/80 mg compared to that with 80/40 mg. Adverse event rates were similar among all treatment groups.
Conclusions: Adalimumab serum concentrations in Chinese patients with CD were comparable to those observed previously in Western and Japanese patients. Clinically meaningful remission rates and improvement in inflammatory markers were achieved with both dosing regimens; changes occurred rapidly with adalimumab 160/80 mg induction therapy. No new safety signals were reported. (Intest Res 2016;14:152-163)
|
|
|
KEYWORD
|
|
|
Crohn disease, Anti-tumor necrosis factor, Adalimumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|